HANMI PHARM SIGNS 3.2 TLN-WON LICENSING DEAL WITH ROCHE'S GENENTECH FOR OBESITY DRUG CANDIDATE - YONHAP
$3.2 trillion-won deal with Genentech signals major validation for Hanmi’s obesity drug candidate.
What changed
$3.2 trillion-won deal with Genentech signals major validation for Hanmi’s obesity drug candidate.
Why it matters
$3.2 trillion-won deal with Genentech signals major validation for Hanmi’s obesity drug candidate. — impact context not separately stored; see What changed.
← Dashboard
Aug 24, 2026 07:10 AM ET